Current treatment strategies for myelodysplastic syndromes

DOI Web Site PubMed
  • SUZUKI Takahiro
    Division of Hematology, Department of Medicine, Jichi Medical University

Bibliographic Information

Other Title
  • MDSの治療
  • MDSの治療 : 薬物療法・移植・支持療法
  • MDS ノ チリョウ : ヤクブツ リョウホウ ・ イショク ・ シジ リョウホウ
  • ―薬物療法・移植・支持療法―

Search this article

Description

Myelodysplastic syndromes (MDS) are myeloid clonal disorders presumably induced by genetic mutations in immature hematopoietic cells. According to the international prognostic scoring system (IPSS or IPSS-R), patients are classified into two groups: lower-risk MDS (LR-MDS) and higher-risk MDS (HR-MDS). A majority of LR-MDS patients manifest refractory cytopenias due to inefficient hematopoiesis, and patients in this group are principally treated with agents stimulating hematopoiesis or differentiation. On the other hand, patients with HR-MDS are at much higher risk of developing leukemia, and thus require prompt hematopoietic stem cell transplantation or chemotherapy. In this section, I will discuss current treatment strategies for MDS in Japan, including future perspectives.

Journal

  • Rinsho Ketsueki

    Rinsho Ketsueki 56 (10), 1985-1995, 2015

    The Japanese Society of Hematology

Related Projects

See more

Keywords

Details 詳細情報について

Report a problem

Back to top